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Background 
Hypoxia and snoring-related mechanical trauma contribute to airway inflammation in obstructive sleep apnoea (OSA). 
Increased exhaled nitric oxide (FENO), an airway inflammation marker, has been reported in OSA patients. We propose 
the measure of NO in the oral cavity (oNO) as marker of oropharyngeal inflammation in OSA. 
Methods 
We compared oNO and FENO of 39 OSA patients with those of 26 mild asthmatics (ASTHMA), 15 patients with 
chronic rhinitis or rhinosinusitis (CRS) and 24 healthy subjects. A special device was used for oNO measurement. 
Apnoea/hypopnoea index (AHI), oxygen desaturation index, mean and nadir SaO2 were calculated from the 
polysomnography. 
Results 
oNO was significantly increased in OSA (104.2 95%CI 80.2–135.5 ppb) as compared to ASTHMA (71.9 95%CI 56.3–
91.9 ppb; p = 0.015), CRS (54.4 95%CI 40.2–73.7 ppb;p = 0.009) and healthy subjects (63.6 95%CI 59–
73 ppb; p < 0.001). oNO was directly related to AHI (r = 0.466, p = 0.003) and to minutes slept with SaO2 <90% 
(r = 0.471,p = 0.011) and it was inversely related to nadirSaO2 (r = −0.393, p = 0.018). FENO was highest in 
asthmatics (40.3 95%CI 32.5–50.1 ppb) and only slightly elevated in OSA (23.1 95%CI 19,8–28.3 ppb) and CRS (22.8 
95%CI 16.8–32.5 ppb). 
Conclusions 
The finding that oral NO is increased in OSA and is related to upper airway obstructive episodes and to hypoxemia 
severity, strengthens the clinical and pathogenic role of oral inflammation in OSA. 
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Introduction 
Obstructive sleep apnoea (OSA) is a sleep disorder that leads to metabolic abnormalities and increased cardiovascular 
risks.1 Airway and systemic inflammation has been proposed to have a central role in the pathophysiology of 
OSA.2 Several studies reported increased inflammatory and oxidative stress markers in lower airway of OSA patients. 
Increased exhaled nitric oxide (FENO) and inflammatory metabolites were detected in the exhaled air of OSA compared 
to healthy subjects.3, 4 and 5 All these markers were positively related to the severity of OSA (apnea / hypopnoea index). 
Airway inflammation in OSA is supposed to be the consequence of the release of inflammatory cytokines due to 
hypoxia and reperfusion cycles during episodes of apnoea or to snoring-related mechanical trauma. Inflammation has 
been described to involve the upper airways including the nose, the uvula, the soft palate and the pharyngolaryngeal 
tract. Local upper airway inflammation promotes oropharyngeal inspiratory muscle dysfunction and progressive local 
neurogenic lesion amplifying upper airway narrowing and collapsibility.6 Localized inflammation with plasma cell 
infiltration and interstitial oedema has been documented in oropharynx, uvula and soft palate biopsies.7 Nitric oxide 
(NO) is a molecule involved in oxidative stress and airway inflammation; reactive metabolites of nitric oxide may cause 
tissue damage through oxidation and nitration.8 The role of nitric oxide in inflammatory airway diseases is well known 
and the usefulness of NO measurement both in the exhaled air and in the nasal cavity in asthma and nasal polyposis is 
widely recognized.9 and 10Increased oral nitric oxide production, evaluated by measuring salivary nitrites and nitrates, has 
been found in inflammatory oral diseases as periodontal disease.11, 12 and 13We previously found that oNO can be non 
invasively assessed using a special device which separates completely the oral cavity from the nose and the lower 
airway. oNO resulted to be significantly increased in healthy subjects during plaque deposition14 and in edentulous 
patients11 We wondered whether in OSA, oropharyngeal inflammation triggered by upper airway vibration, might lead 
to increased oral NO production. 
The objective of the study was to determine whether oral nitric oxide production is increased in OSA patients and is 
related to disease severity. To this purpose we assessed oNO and FENO in patients with OSA as compared to patient 
with mild asthma and chronic rhinosinusitis (lower and upper airway inflammatory diseases respectively).  
Methods 
Patients 
Thirty nine consecutive OSA patients diagnosed at the Sleep Medicine Center by polysomnography in the period June 
2007–December 2008, were enrolled. Polysomnography was performed according to American Academy of Sleep 
Medicine Standards of Practice Committee of the American Sleep Disorders Association guidelines,15 and OSA was 
diagnosed when the apnoea/hypopnoea index (AHI) was over 10 episodes per hour. Exclusion criteria were current 
smoking, past or present history of lower and upper airway disease (asthma, allergic rhinitis, chronic rhinosinusitis), 
respiratory infections during the last 8 weeks, systemic disease, use of corticosteroids in the last 2 months, dentures 
wearing, periodontal disease or coexisting oral disease. OSA patients were compared to 15 non smoking patients with 
chronic rhinitis or rhinosinusitis (CRS), and to 26 non smoking patients with mild asthma (ASTHMA). Asthma and 
CRS patients were selected among those followed-up in our clinic, who were not receiving oral or inhaled 
corticosteroids and had no oral or periodontal disease. Diagnosis and classification of rhinitis / rhinosinusitis and asthma 
were performed according to ARIA16 and 17 and GINA18 guidelines respectively. Twenty four non smoking, non obese, 
healthy subjects (HS), with no oral disease, with a mean age of 41 years (range 18–65, 10 men and 14 women) served 
as control group for oNO measurement. 
The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the local ethics 
committee. All the patients gave their informed consent for the use of their data in the study. 
Study design 
All subjects underwent history recording, clinical examination, lung function tests, and measurement of oNO and FENO. 
Polysomnography 
Overnight attended polysomnography was performed using an H2O system for ambulatory recording (Grass-Telefactor; 
ASTRO-Med; West Warwick, RI) according to the guidelines of the American Academy of Sleep Medicine Standards 
of Practice Committee of the American Sleep Disorders Association,15 using two EEG channels, two electrooculogram 
channels, surface mentalis and bilateral anterioris tibialis electromyography, electrocardiography, oronasal air flow 
(two-channel thermistor), respiratory movements (thoracic and abdominal belts), snoring and body position, and arterial 
oxygen saturation (SaO2). Standardized criteria for staging sleep were used. EEG tracings were used to assess the total 
sleep time. Apnea was defined as complete cessation of air flow of at least 10 s in duration, and hypopnea as >50% 
amplitude reduction of air flow lasting 10 s, associated with 4% oxyhemoglobin desaturation during sleep. From the 
polysomnography tracing were calculated the following: AHI, oxygen desaturation index (ODI; number of 
oxyhemoglobin desaturations per hour of sleep), mean and nadir SaO2 and minutes slept with a SaO2 below 90% 
(SaO2 < 90%) 
Lung function tests 
Spirometry was performed using the computerized spirometer BAIRES (Biomedin, Padova, Italy). At least three 
maximal and repeatable flow-volume curves with vital capacity (VC) within 5% were recorded. From the curve with 
the greatest VC and maximal inspiratory and expiratory efforts, were calculated FEV1, FEV1/VC ratio, forced mid 
expiratory flow (FEF50) and forced mid-inspiratory flow (FIF50) and their ratio (FEF50/FIF50). VC, FEV1 and FEF50 were 
expressed as percent of predicted.19 
Exhaled nitric oxide measurement 
Fractional Exhaled Nitric Oxide (FENO) was measured according to ATS/ERS recommendations20 with a NO 
chemiluminescent analyzer (Sievers NOA 280, Sievers, Boulder, CO, USA) using a sampling flux of 50 mL/min. 
FENO values were calculated upon an end expiration plateau 3 s long at least. The patient performed three acceptable 
trials and the mean value was registered. 
 
 
Oral nitric oxide measurement 
Oral NO production was measured using a special device which consisted of a holed metal tube, welded at right angle 
to a shaped plate which served to press the tongue against the soft palate so as to isolate the mouth from upper and 
lower airway and from gastric cavity. Before the measurement, the subjects were asked to rinse accurately their mouth 
with tap water. A soft mouthpiece was fitted on the tube, to mantain the mouth closed off and to fasten the position of 
the device. A two-way valve connected the plate to a glass syringe, for delivery and withdrawal of air samples to and 
from the oral cavity, and, through a wide-bore Teflon tube (internal diameter 2 mm), to the NO meter (Fig. 1) Thirty ml 
NO-free air (NO below 5 ppb) were injected with a glass syringe through the device into the closed empty mouth and 
maintained for 30 s; the air was then withdrawn and shifted to the NO chemiluminescence analyzer (SIEVERS 280 
NOA, Boulder, CO).14 oNO measurement was repeated until three values having a variability within 5% were obtained. 
The mean of the three values was used in the analysis. 
 
Statistics 
Data were analysed with the statistical SPSS software package (version 13.0 for Windows, Chicago, IL, USA). Normal 
distribution of variables were assessed according to Kolmogorov-Smirnov's test of normality. In case of non normal 
distribution the variables were computed as logarithmic. Comparisons between continuous variables were estimated 
with unpaired and paired Student's t test or Mann-Whitney test, depending on the distribution of the variables. 
Categorical variables were compared with the Fisher's exact test. Correlations between parametric or non parametric 
variables were obtained using Pearson's regression analysis, Spearman's rank correlation tests, and logistic regression 
analysis. For the correlations of oNO with sleep disturbance, the following sleep parameters were used: AHI, oxygen 
desaturation index (ODI; number of oxyhemoglobin desaturations per hour of sleep), mean and nadir SaO2, and 
SaO2 < 90%. 
A p value < 0.05 was considered to be significant. 
 
Results 
Demographical and clinical characteristics of patients are reported in Table 1. OSA patients, as compared to ASTHMA 
and CRS patients, had significantly older age, higher prevalence of males and higher BMI. These differences reflect the 
characteristics of the diseases, OSA being more frequent in obese men, adult asthma in women. There were no 
difference in lung function parameters apart from a significantly higher FEF50/ FIF50 ratio in OSA patients compared 
to asthmatics (p = 0.05). 
 
Nitric oxide measurements 
Mean values of oral NO in patients and healthy controls are reported in Fig. 2, panel A. OSA patients had significantly 
increased oNO values (104.2 95%CI 80.2–135.5 ppb) as compared either with healthy subjects (63.6 95%CI 59.0–
73.0 ppb; p < 0.001) or with both ASTHMA (71.9 95%CI 56.3–91.9 ppb; p = 0.015) and CRS patients (54.4 95%CI 
40.2–73.7 ppb; p = 0.009). In both ASTHMA and CRS groups oNO was similar to that of healthy controls. 
 
Mean FENO values in patients and controls are reported in Fig. 2, panel B. In OSA patients FENO values (23.1 95%CI 
19,8–28.3 ppb) were significantly higher than in healthy subjects (11.0 95%CI 8.7–14.8 ppb; p < 0.001), and were 
similar to those observed in CRS patients (22.8 95%CI 16.8–32.5 ppb). ASTHMA patients had the highest 
FENO values (40.3 95%CI 32.5–50.1 ppb). 
No significant relationship between oNO and FENO was found either in OSA or in CRS, and in ASTHMA. 
In OSA patients, oNO production was related to the severity of sleep disturbances. Actually, oNO was significantly 
positively related to AHI (r = 0,466, p = 0.003) (Fig. 3, A), to ODI (r = 0.447, p = 0.017), to SaO2 < 90% (available in 
27 of the 39 patients) (r = 0.471,p = 0.011) (Fig. 3, B) and negatively related to nadir SaO2 (r = −0.393, p = 0.018). 
oNO was significantly related to BMI (r = 0.505, p < 0.001). 
No correlation was found between oNO and spirometric parameters. 
 
Discussion 
The results of the present study show that patients with OSA have increased production of NO in oral cavity, which is 
proportional to the severity of the disease. Since NO is an inflammatory marker, this finding is in line with prior studies 
showing inflammation in the pharynx, uvula, soft palate and oral cavity of OSA patients.6 and 7 Oral inflammation in 
OSA is supposed to originate in the upper airway, where repetitive closing and opening during apnoeic episodes leads 
to increased production of inflammatory cytokines.21 Pharyngeal collapse is favoured by obesity, that is recognized as 
a major risk factor for OSAS. This may explain the correlation we found between BMI and oNO values. Oral 
inflammation in OSA may also be a consequence of intermittent hypoxia and reperfusion.22 Low oxygen tension is a 
known trigger of activation of polymorphonuclear neutrophils and macrophages, that interact with the endothelium 
causing the release of free oxygen radicals.23 Increased oNO, interacting with free oxygen radicals, may amplify the 
oxidative and nitrosative stress by generating reactive nitrogen oxide species.24 The effect of hypoxia on NO release is 
supported by the significant inverse correlation we found between oNO levels and nadir overnight desaturation. 
Interestingly, oral NO in OSA patients was significantly higher than in patients with other types of upper and lower 
inflammatory diseases, such as rhinosinusitis and asthma. Actually, in both asthma and CRS the major sources of NO 
production are far from the mouth, paranasal sinuses in CRS,24 bronchi and alveoli in asthma.25 These differences in 
NO source are reflected by findings of exhaled nitric oxide measurements. In fact, FENO was highest in asthmatic 
patients and mildly increased in both patients with CRS and those with OSA. The mild increase of FENO levels in OSA 
patients is in agreement with several studies reporting increased inflammatory markers and metabolites in the exhaled 
air and condensate of OSA patients.3, 4 and 5 FENO levels measured in OSAS may reflect a systemic inflammatory 
response.26 
In conclusion, the findings of this study indicate that oral nitric oxide measurement in OSA may be used as a marker of 
upper airway obstructive episodes due to mechanical trauma and of hypoxemia causing local oropharyngeal 
inflammation. Follow-up measurements of oNO after effective CPAP therapy would strengthen these findings. Oral 
NO, through its ability to amplify oxidative and nitrosative stress, may be suggested to have a pathogenetic role in 
OSA. 
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Figure 1.  
Illustration of oral NO device. Siringe with NO-free air (1); two-way valve for delivery and withdrawal of air sample to 
and from the oral cavity and to the NO meter (2); wide-bore teflon tube (3); soft mouthpiece (4); Holed metal tube 
welded at a right angle to a shaped plate (5). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 
Demographical and clinical characteristics of OSA patients compared to ASTHMA and CRS groups. 
 OSA (N = 39) ASTHMA (N = 26) CRS (n = 15) 
Age, [range] 66 [38–81]a and b 45 [17–68] 50.4 [29–71] 
Sex (M/F) 22/17a and c 8/18 6/9 
BMI 30.7 (28.8–32.7)a and c 24.1 (22.6–25.5) 23.9 (21.9–25.9) 
FVC 100.7 (92.9–108.5) 107.7 (99.9–115.5) 113.1(100.5–125.7) 
FEV1 99.4 (91.1–107.8) 92.6 (85.8–99.4) 99.7 (86.7–112.7) 
FEV1/VC 76.7 (73.5–79.9) 72.7 (67.9–77.3) 73.4 (67.3–79.5) 
FEF50/ FIF50 112.7 (91.7–133.6)d 77.6 (52.6–102.7) 87 (62.7–111) 
 
BMI,FVC, FEV1, FEV1/VC, FEF50/ FIF50 are reported as means with 95% confidence intervals. 
 
a p < 0.001 OSA vs ASTHMA 
b p < 0.05 OSA VS CRS 
cp < 0.001 OSA vs CRS 
dp < 0.05 OSA VS ASTHMA 
 
 
 
 
 
 
Figure 2.  
Geometric means and SD (bars) of oNO (A) and FENO (B) in patients with OSA compared to asthmatics (ASTHMA), 
chronic rhinitis and rhinosinusitis (CRS) and healthy subjects (HS). #p < 0.001 OSA versus HS; ‡p < 0.05 OSA versus 
ASTHMA; * p < 0.05 OSA vs CRS. †p < 0.05 ASTHMA versus CRS;¥p < 0.001 ASTHMA versus HS; ×p < 0.05 CRS 
versus HS. 
 
 
 
 
 
 
Figure 3.  
Correlation of oNO with AHI (A) and with SaO2 < 90% (B) in OSA patients. 
 
 
 
